{
    "ticker": "ONVO",
    "name": "Organovo Holdings, Inc.",
    "description": "Organovo Holdings, Inc. is a pioneering biotechnology company that specializes in 3D bioprinting technology for the development of functional human tissues. Founded in 2012, Organovo aims to revolutionize the fields of medicine and drug development by creating living human tissues that can be used in research, drug testing, and ultimately for therapeutic applications. The company's proprietary 3D bioprinting platform allows for the precise construction of human tissues that mimic the structure and function of natural tissue, which can significantly enhance the way drugs are developed and tested. Organovo's products include liver and kidney tissues that are utilized by pharmaceutical and biotechnology companies to conduct more accurate preclinical testing. This innovative approach not only improves the efficiency of drug development but also reduces the reliance on animal testing. Organovo is committed to advancing regenerative medicine and is actively working on expanding its tissue offerings and applications. The company envisions a future where engineered human tissues can be used for transplantation, addressing critical shortages in organ availability and improving patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2012",
    "website": "https://www.organovo.com",
    "ceo": "Taylor C. J. W. H. McGowan",
    "social_media": {
        "twitter": "https://twitter.com/Organovo",
        "linkedin": "https://www.linkedin.com/company/organovo/"
    },
    "investor_relations": "https://ir.organovo.com",
    "key_executives": [
        {
            "name": "Taylor C. J. W. H. McGowan",
            "position": "CEO"
        },
        {
            "name": "C. Scott G. T. M. C. P. P. N. P. O. D. P. J. M. W. L. M. K. H.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Bioprinted Tissues",
            "products": [
                "Human Liver Tissue",
                "Human Kidney Tissue"
            ]
        },
        {
            "category": "Research Services",
            "products": [
                "Tissue Testing Services"
            ]
        }
    ],
    "seo": {
        "meta_title": "Organovo Holdings, Inc. | 3D Bioprinting for Human Tissues",
        "meta_description": "Learn about Organovo Holdings, Inc., a leader in 3D bioprinting technology for developing functional human tissues for research and therapeutic applications.",
        "keywords": [
            "Organovo",
            "3D Bioprinting",
            "Biotechnology",
            "Human Tissues",
            "Drug Development",
            "Regenerative Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is Organovo known for?",
            "answer": "Organovo is known for its innovative 3D bioprinting technology that creates functional human tissues for drug testing and research."
        },
        {
            "question": "Who is the CEO of Organovo?",
            "answer": "The CEO of Organovo is Taylor C. J. W. H. McGowan."
        },
        {
            "question": "Where is Organovo headquartered?",
            "answer": "Organovo is headquartered in San Diego, California, USA."
        },
        {
            "question": "What products does Organovo offer?",
            "answer": "Organovo offers bioprinted human liver and kidney tissues, as well as tissue testing services."
        },
        {
            "question": "When was Organovo founded?",
            "answer": "Organovo was founded in 2012."
        }
    ],
    "competitors": [
        "AVXL",
        "CRIS",
        "BMRN",
        "REGN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BIIB"
    ]
}